Skip to main content

Monday, June 5th, 2017 BREAKING NEWS and Tute Ownership

Institutional investors quadrupled their ownership this year.

VOCLOSPORIN  is BETTER than we thought!! New analyses of data reveal the power, as the press release notes:

“We were very encouraged to observe that voclosporin therapy resulted in significantly improved remission rates without compromising renal function and blood pressure or inducing electrolyte disorders,” stated Dr. Tumlin, Principal Investigator. “Prolonged steroid therapy for lupus nephritis is associated with unwanted side-effects, and a reduction in steroid dose should be a treatment goal. These encouraging data suggest that voclosporin can induce clinical remissions with low dose steroids while minimizing renal toxicity.”

This should explain why tute ownership is way up!
Check out this website to see how tutes have nearly quadrupled their ownership over the last five months.  This should assure you that you're on the right side of this bet as a long, and that the shorts are just playing with fire. Hang in there longs, we're going to get there.

And on an unrelated issue, I want to thank the Stock Twits community, including the managers of ST, for running a great site, and for their support of the Auphians. Stock is a GREAT place to check in with fellow investors, and to scan for links to in depth stories.  The Auphians is intended to complement, not compete with or replace Stock Twits, by providing a safe space for longer comments and in depth analyses.

Best regards to all,

Trading Cyclist  (aka TC)



Comments

  1. UnknownJune 5, 2017 at 8:40 AM

    Aurinia presents the additional data...


    https://finance.yahoo.com/news/aurinia-presents-additional-data-phase-120000334.html

    ReplyDelete
    Replies
    1. Trading CyclistJune 5, 2017 at 8:48 AM

      Thanks Jess. Curious we're going down on such good news. Kind of like Ariad, no?? And frankly, if like Ariad, I can live with that!!

      Delete
    2. vidpok45June 5, 2017 at 9:24 AM

      TC, the same entities that manipulated the Ariad shares appear to be doing the same here. In fact, I wouldn't doubt that BR is a paid agitator for these well organized groups as their manipulative techniques are so totally similar. The really great news is that they dont suppress the bad companies, just companies with great prospects like AUPH but which are thinly traded and easily manipulated. In the end it will matter not at all. I have every expectation that we will exceed the very decent return on Ariad. Just a matter of time. Plenty of dry powder if the mms take this low enough, it is going to be a spectacular buyout.

      Delete
    3. UnknownJune 5, 2017 at 10:04 AM

      What does that tell you when you have overwhelming assets of good data/studies/articles and the price still is going down, it's beyond laughable. If you are an educated investor, this shouldn't affect you at all because you know that the bottom line is that the company will be bought sooner or later, or the pps will eventually appreciate at the end of the day(p3 conclusion). With the p3 design being the same as p2 being that the only difference is the number of patients, so we know already know the percentage of responses to the drug will remain the same as we've been seeing it in the past two months. They are insulting our intelligence...jmo.🤑🤑🤑

      Delete
    4. Lunacy aka John GaltJune 5, 2017 at 10:10 AM

      I'll even go as far and predict better response rates in Ph3 due to a healthier patient population with better access to standard healthcare.

      Delete
    5. Trading CyclistJune 5, 2017 at 10:14 AM

      Yup, it's the same damn game. And I agree that BR is likely a paid agitator, who else could be so shameless with their idiocy? And do you remember when we were sharing our personal details, there was not a PEEP from him? I'm starting to think that "he" is not really a person, but really just a "bot" or fake profile that's managed by some hedge fund. They probably use the "BR Profile" to write BS about any stock they want to run down. There's probably even a training manual on "how to sound like BR" so retail folks are fooled into thinking he/she/it is a real person, which it absolutely can't be. Also, BR's mastery of the TOR on LieHub is uncanny, no sane individual would bother to snuff out all positive posts like that. Also, no amateur could possibly take over the entire thread, and completely hijack the narrative. Those are professional grade skills.

      Delete
  2. vidpok45June 5, 2017 at 9:30 AM

    If we can get Dr. Glickman to attend the victory party in Victoria, how about we get a plane to carry a banner reading
    "Congratulations Dr. Glickman" or words to that effect. It should be a great day. Maybe some fireworks also or is that too "over the top"?

    ReplyDelete
    Replies
    1. Trading CyclistJune 5, 2017 at 10:09 AM

      I'm completely up for the victory party, all the more so if we can get The Glick to attend. And I'll chip in for the plane!!

      Delete
  3. Trading CyclistJune 5, 2017 at 10:15 AM

    Missed Luna's comment. I completely agree that P3 is like to yield better results, for precisely the reasons that you state!!

    ReplyDelete
  4. vidpok45June 5, 2017 at 11:17 AM

    I was pleased to read that unlike other CNIs, Voclosporin does not cause electrolyte imbalances including hyperkalemia or hypomagnesemia.

    Hyperkakemia can cause these already sick LN patients to feel tired, experience paresthesias (neuritic symptoms), become nauseated, have trouble breathing, experience chest pains, and have irregular heartbeats.

    Hypomagnesemia can cause muscle weakness or tightness, tremors, irritability, insomnia, paresthesias, and fatigue.

    These already severely ill LN patients can be made to feel even sicker by the currently available CNIs. Voclosporin promises to be much more effective without these adverse side effects.

    ReplyDelete
  5. SueJune 5, 2017 at 12:04 PM

    This comment has been removed by the author.

    ReplyDelete
    Replies
    1. SueJune 5, 2017 at 12:05 PM

      This comment has been removed by the author.

      Delete
  6. vidpok45June 5, 2017 at 4:18 PM

    Without anyone to refute his bullshit, BR is able to post as much disinformation as he wants over on liehub. I hope some here who don't care about the liehub administrators probable response, stand up to his crap and call him out for the lying POS he is.

    ReplyDelete
    Replies
    1. YorkTigerJune 5, 2017 at 4:47 PM

      Did you see that latest post?

      Delete
    2. Trading CyclistJune 5, 2017 at 8:21 PM

      No, and it makes me a little sick to go there. What did he say?

      Delete
  7. Trading CyclistJune 5, 2017 at 8:22 PM

    LieHub is a filthy, sickening mess. BR rins the show and floods that space to lies and disinformation. It would be a public service to just take it off line.

    ReplyDelete
    Replies
    1. GreggorsJune 6, 2017 at 3:06 AM

      Couldn't what BR does be considered a form of Spam? Ihub admins may need a better argument to ban him or it.

      Delete

Post a Comment

Popular posts from this blog

June 6, 2017. Buy Out at 63?

Take a spin on our BO pricing model! The Trading Cyclist Our model is generating a range of $35-63 BO PPS , per the low/high case scenarios below - where only the Voc  price  is different (25 k vs 50k). My hunch is that this is both conservative and in the ballpark.  It's conservative b/c: 1) patient population is consistent with Aurinia's projection; 2) assumes only 35% of population on treatment; 3) assumes 75% discount for European market; 4) pricing is at 50% of range projected by Aurinia; 5) uses target P/S ratio of 3, which is below Biotech industry average of 5.0.  Outcome   Patient Pool  (Same for both Scenarios)  Pricing :  Price/Sales ratio   Here's the  Link to the model Low end BO PPS w/30% discount:  $35  ($50 no discount)  High End BO PPS w/30% discount  $63  ($90 no discount)  Prev: 26.5 per 100,000 (Based on epidemiological study)  Total Patient po...
25 comments
Read more

June 8, 2017: The case for early approval of Voclosporin

Voclosporin will likely be approved well before the P3 trial runs it course. Here's how it's going to work.  First, there's a legal and regulatory path for this approval .  While I quote the relevant passage below, here's the link to the  FDA Regulations , as well as  a   list of drugs   t hat received accelerated approval.  Sec. 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoin t that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that ...
16 comments
Read more

iHub has been hijacked by trolls

Yup. iHub can't get rid of "Biotech Researcher," aka BR.  It's both a win for BR (the troll), and a huge loss for iHub. Their platform loses value and credibility when they refuse to take action on perma-trolls that derail the discussion and distract investors from their efforts to just honestly share information and opinions on the equities they own. So shame on iHub for not taking action to resolve this. I'm going to cease and desist on posting there until the troll (BR) problem has been resolved, and credible, valuable posters have been reinstated. I've already cancelled my premium membership some time ago. I suggest you do the same. With kind regards to all Trading Cyclist (aka TC)
53 comments
Read more